VYNE Therapeutics Inc. (VYNE) NASDAQ
0.59
+0.0039(+0.66%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.59
+0.0039(+0.66%)
Currency In USD
Address
520 U.S. Highway 22
Bridgewater, NJ 08807
United States of America (the)
Phone
800 775 7936
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
January 25, 2018
| Name | Title | Pay | Year Born |
| David T. Domzalski | Chief Executive Officer, President & Director | 1.01M | 1967 |
| Darrell S. Rigel | Consultant | 40,200 | 1951 |
| Mutya Harsch | General Counsel, Chief Legal Officer & Company Secretary | 624,640 | 1975 |
| Iain A. Stuart | Chief Scientific Officer | 641,555 | 1973 |
| Tyler Zeronda | Chief Financial Officer & Treasurer | 0 | 1986 |
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.